Summary of results for people diagnosed with or undergoing surgery for bowel cancer (2023), in England and Wales



Care pathways

37,730 people

were diagnosed with bowel cancer in England and Wales between 1 January 2023 and 31 December 2023. England: 35,243 people Wales: 2,487 people

Proportion of people who presented with stage 1 or stage 2 cancer



Proportion of people recorded as being seen by a clinical nurse specialist (CNS)




% of people with CNS data available England: 69% Wales 99%

% of people with CNS data available who were seen by a CNS: Target >95%

England: 93% Wales 93%

Number of patients who presented with colorectal cancer by route of diagnosis*



* Data were impacted by the COVID-19 pandemic

Proportion of all people with histologically confirmed Stage 4 disease in England with a record of genetic tumour profiling (KRAS, NRAS, BRAF)



66% 2019-2021

Data on genomic tests is only available for people diagnosed in England between 1 January 2019 - 31 December 2021.

75 out of 119 NHS trusts excluded due to incomplete data submission.

Peri-operative care



3.1% 2019 to

% of people who died within 90 days of surgery (year of surgery): Target ≤6%



11.1% 2019 to

11.9% 2023

% of people with an unplanned 30day readmission after surgery (year of surgery): Target: <15%



8.0% 2019

to

6.8% 2023

% of people with an unplanned 30day return to theatre after surgery (year of surgery): Target <10%



2023

% of trusts/multidisciplinary teams (MDTs) that performed ≥ 20 major rectal cancer operations per year (year of surgery)*



April 2018

March 2023

% of people with an unclosed diverting ileostomy 18-months after anterior resection (major rectal cancer surgery, year of surgery, data were impacted by the COVID-19 pandemic)*: Target <35%



66% 2019

to

75% 2023

% of people who underwent major colorectal cancer surgery with a minimally invasive approach (laparoscopic or robotic, year of surgery)

Oncological management



April 2021 to October 2023

% of people who received adjuvant chemotherapy for stage 3 colon cancer (year of surgery)*: Target >55%

April 2021 to October 2023

% of people who experienced severe acute toxicity after adjuvant chemotherapy (year of surgery)*: Target <33%



34% 2019 to

33% 2023

% of people with rectal cancer who received neo-adjuvant radiotherapy treatment (year of diagnosis): Target 10%-60%

82.3%

April 2020 to March 2021

84.9%

April 2021 to March 2022

% of people alive 2-years after major colorectal cancer surgery (year of surgery): Target >70%

All results relate to people in England and Wales, except for genetic tumour profiling which is only available in England.

^{*} Comparator not available due to change in time periods or overlap in time periods